PMID- 22077999
OWN - NLM
STAT- MEDLINE
DCOM- 20121214
LR  - 20220318
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 13
IP  - 6
DP  - 2011
TI  - Adiponectin associates with markers of cartilage degradation in osteoarthritis 
      and induces production of proinflammatory and catabolic factors through 
      mitogen-activated protein kinase pathways.
PG  - R184
LID - 10.1186/ar3512 [doi]
AB  - INTRODUCTION: Adiponectin is an adipokine that regulates energy metabolism and 
      insulin sensitivity, but recent studies have pointed also to a role in 
      inflammation and arthritis. The purpose of the present study was to investigate 
      the association and effects of adiponectin on inflammation and cartilage 
      destruction in osteoarthritis (OA). METHODS: Cartilage and blood samples were 
      collected from 35 male OA patients undergoing total knee replacement surgery. 
      Preoperative radiographs were evaluated using Ahlback classification criteria for 
      knee OA. Circulating concentrations of adiponectin and biomarkers of OA, that is, 
      cartilage oligomeric matrix protein (COMP) and matrix metalloproteinase 3 
      (MMP-3), were measured. Cartilage samples obtained at the time of surgery were 
      cultured ex vivo, and the levels of adiponectin, nitric oxide (NO), IL-6, MMP-1 
      and MMP-3 were determined in the culture media. In addition, the effects of 
      adiponectin on the production of NO, IL-6, MMP-1 and MMP-3 were studied in 
      cartilage and in primary chondrocyte cultures. RESULTS: Plasma adiponectin levels 
      and adiponectin released from OA cartilage were higher in patients with the 
      radiologically most severe OA (Ahlback grades 4 and 5) than in patients with less 
      severe disease (Ahlback grades 1 to 3). Plasma adiponectin concentrations 
      correlated positively with biomarkers of OA, that is, COMP (r = 0.55, P = 0.001) 
      and MMP-3 (r = 0.34, P = 0.046). Adiponectin was released by OA cartilage ex 
      vivo, and it correlated positively with production of NO (r = 0.43, P = 0.012), 
      IL-6 (r = 0.42, P = 0.018) and MMP-3 (r = 0.34, P = 0.051). Furthermore, 
      adiponectin enhanced production of NO, IL-6, MMP-1 and MMP-3 in OA cartilage and 
      in primary chondrocytes in vitro in a mitogen-activated protein kinase 
      (MAPK)-dependent manner. CONCLUSIONS: The findings of this study show that 
      adiponectin is associated with, and possibly mediates, cartilage destruction in 
      OA.
FAU - Koskinen, Anna
AU  - Koskinen A
AD  - The Immunopharmacology Research Group, University of Tampere School of Medicine 
      and Tampere University Hospital, Medisiinarinkatu 3, Tampere, FI-33014, Finland.
FAU - Juslin, Sami
AU  - Juslin S
FAU - Nieminen, Riina
AU  - Nieminen R
FAU - Moilanen, Teemu
AU  - Moilanen T
FAU - Vuolteenaho, Katriina
AU  - Vuolteenaho K
FAU - Moilanen, Eeva
AU  - Moilanen E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111111
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers)
RN  - 0 (Cartilage Oligomeric Matrix Protein)
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Flavonoids)
RN  - 0 (Glycoproteins)
RN  - 0 (Interleukin-6)
RN  - 0 (Matrilin Proteins)
RN  - 0 (TSP5 protein, human)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
RN  - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
SB  - IM
CIN - Arthritis Res Ther. 2012;14(3):402. PMID: 22716456
MH  - Adiponectin/blood/*metabolism/pharmacology
MH  - Aged
MH  - Biomarkers/blood
MH  - Blotting, Western
MH  - Cartilage/drug effects/*metabolism
MH  - Cartilage Oligomeric Matrix Protein
MH  - Cells, Cultured
MH  - Chondrocytes/cytology/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Extracellular Matrix Proteins/blood/metabolism
MH  - Flavonoids/pharmacology
MH  - Glycoproteins/blood/metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Interleukin-6/metabolism
MH  - MAP Kinase Signaling System/drug effects
MH  - Male
MH  - Matrilin Proteins
MH  - Matrix Metalloproteinase 1/metabolism
MH  - Matrix Metalloproteinase 3/blood/metabolism
MH  - Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism
MH  - Nitric Oxide/metabolism
MH  - Osteoarthritis/blood/*metabolism/pathology
MH  - Severity of Illness Index
MH  - Tissue Culture Techniques
PMC - PMC3334633
EDAT- 2011/11/15 06:00
MHDA- 2012/12/15 06:00
PMCR- 2011/11/11
CRDT- 2011/11/15 06:00
PHST- 2011/08/24 00:00 [received]
PHST- 2011/10/25 00:00 [revised]
PHST- 2011/11/11 00:00 [accepted]
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2012/12/15 06:00 [medline]
PHST- 2011/11/11 00:00 [pmc-release]
AID - ar3512 [pii]
AID - 10.1186/ar3512 [doi]
PST - ppublish
SO  - Arthritis Res Ther. 2011;13(6):R184. doi: 10.1186/ar3512. Epub 2011 Nov 11.